![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1529881
¼¼°èÀÇ ¼Ò¾Æ ½ÉÀå ¼ö¼ú ½ÃÀå : ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® - ¼ö±âº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2024-2030³â)Pediatric Cardiac Surgery Market Size, Share & Trends Analysis Report By Procedure (Interventional Procedures, Peripheral Vascular Procedures), By End-use (Hospitals, Specialty Centers), By Region, And Segment Forecasts, 2024 - 2030 |
¼¼°èÀÇ ¼Ò¾Æ ½ÉÀå ¼ö¼ú ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 156¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2030³â±îÁö CAGR 9.8%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â °ÍÀº ÁÖ·Î ¼Ò¾Æ¿¡¼ ¼±Ãµ¼º ½ÉÀå Áúȯ°ú ½ÉºÎÀüÀÇ ¹ß»ý·üÀÇ »ó½ÂÀÔ´Ï´Ù. ºòÅ丮¾Æ¿¡ µû¸£¸é ½Å»ý¾ÆÀÇ ¾à 1%°¡ ¼±Ãµ¼º ½ÉÀ庴(CHD)À» °®°í žÀ¸¸ç, ±× Áß Àý¹Ý ÀÌ»óÀÌ ÁßÁõÀ¸·Î Ä¡·á°¡ ÇÊ¿äÇÏ´Ù°í ÇÕ´Ï´Ù. °Ô´Ù°¡ 2023³â 3¿ù¿¡ ¹ßÇ¥µÈ ¹ü¹Ì º¸°Ç±â±¸(Pan American Health Organization)ÀÇ Á¶»ç¿¡ µû¸£¸é »ýÈÄ 4ÁÖ°£ ¼±Ãµ¼º ÀÌ»óÀ¸·Î »ç¸ÁÇÏ´Â ½Å»ý¾Æ´Â ¼¼°è¿¡¼ ÃßÁ¤ 30¸¸ 3,000¸í¿¡ À̸¨´Ï´Ù.
¶ÇÇÑ CPB ȸ·Î ¼³°è, ¸ð´ÏÅ͸µ ±â¼ú, °ü·ù ¹æ¹ý, ¿Âµµ Á¦¾î, ½É±Ù º¸È£ µîÀÇ ±â´É °È°¡ ÁøÇàµÇ¾î ¼Ò¾Æ ½ÉÀå ¼ö¼úÀÇ ÀÓ»ó ¼ºÀûÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 4¿ù, LivaNova´Â ¼ºÀÎ ¹× ¼Ò¾Æ ȯÀÚÀÇ °³½É¼úÀ» Áö¿øÇϵµ·Ï ¼³°èµÈ ÃÖ÷´Ü ½Ã½ºÅÛÀÎ Essenz Perfusion SystemÀ» Ãâ½ÃÇß½À´Ï´Ù. À̰ÍÀº °í±Þ ¿¡¼¾½º ½ÉÆó ÀåÄ¡(HLM)¿Í Á÷°üÀûÀΠȯÀÚ ¸ð´ÏÅÍ ¹× Á¤¹Ð °¨Áö ±â¼úÀ» ÅëÇÕÇÕ´Ï´Ù. ÀÌ ÅëÇÕÀº ¾ÈÀüÇÑ ½ÉÆó ¿ìȸ(CBP) °ü¸®¸¦ À§ÇÑ µ¥ÀÌÅÍ Áß½ÉÀÇ ÀÇ»ç °áÁ¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.
Ư¼ö ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ, ½Å»ý¾Æ¿ë CPB »ê¼ÒÈ ÀåÄ¡, Àú ÇÁ¶óÀÓ·® »ê¼ÒÈ ÀåÄ¡, ÅëÇÕ µ¿¸Æ ÇÊÅÍ µîÀÇ Çõ½ÅÀûÀÎ ±â¼ú¿¡ ÀÇÇØ ½Å»ý¾Æ¿Í À¯¾ÆÀÇ º¹ÀâÇÑ ¼±Ãµ¼º ½ÉÀå ÀÌ»óÀÇ Ä¡·á ¼ºÀûÀÌ °³¼±µÇ¾î Ä¡·áÀÇ ¿É¼ÇÀÌ ÆîÃÄÁý´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 11¿ù Ortho-Clinical Diagnostics´Â 'VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrators'¶ó´Â ÀÇ·á±â±âÀÇ FDA¿¡ ÀÇÇÑ 510(k) ½ÃÆÇÀü ½Å°í¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ·¯ÇÑ 510(k) ½ÅûÀÇ ¸ñÀûÀº VITROS HIV Combo Reagent Pack ¹× Calibrators°¡ ÇÁ·¹µðÄÉÀÌÆ® µð¹ÙÀ̽ºÀÎ VITROS ECi/ECiQ Immunodiagnostic System HIV Combo Assay¿Í ½ÇÁúÀûÀ¸·Î µ¿µîÇÏ´Ù´Â °ÍÀ» Áõ¸íÇÏ´Â °ÍÀÔ´Ï´Ù.
Á¤ºÎ´Â ¼Ò¾Æ ½ÉÀå ¼ö¼ú ½Ã¼³ °³¼±¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 10¿ù¿¡´Â ¼±Ãµ¼º ½ÉÀå ¼ö¼ú ºÐ¾ß¿¡¼ »õ·Î¿î ±Ç°í°¡ ¹ßÇ¥µÇ¾î ¼±Ãµ¼º ½ÉÀå¿Ü°úÇÐȸ(CHSS)ÀÇ ¸®´õ½ÊÇÏ¿¡ °³¹ßµÇ¾ú½À´Ï´Ù. ÀÌ ÇÐȸ´Â ÀÌ ºÐ¾ßÀÇ 1ÀÎÀÚ·Î ±¸¼ºµÈ ±ÇÀ§ ÀÖ´Â Á¶Á÷ÀÔ´Ï´Ù. ÀÌ ±Ç°íÀÇ Ã¥Á¤¿¡´Â 15ÀÇ Àú¸íÇÑ ÀÇÇÐ ¹× ¿Ü°úÇÐȸ°¡ Çù·ÂÇϰí ÀÖ¾î Á¾ÇÕÀûÀ̰í ÇÐÁ¦ÀûÀÎ ¾îÇÁ·ÎÄ¡°¡ ÃëÇØÁö°í ÀÖ´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù.
¼Ò¾Æ¿ë °ü·ù Á¦Ç°À» »ý»êÇϱâ À§ÇÑ ÅõÀÚ¿Í ÀÚ±Ý Á¶´Þ Áõ°¡µµ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ±â¾÷Àº ¼Ò¾Æ CPB¿¡ Æ¯ÈµÈ ÃÖ÷´Ü ±â¼ú°ú ±â¼úÀ» °³¹ßÇϰí, Ä¡·áÀÇ ÁúÀ» ³ôÀ̰í, ÀÌ¿ë °¡´ÉÇÑ Ä¡·á ¿É¼ÇÀÇ ÆøÀ» ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 8¿ù Boston ScientificÀº ¼±Ãµ¼º ½ÉÀ庴À» °¡Áø ¼Ò¾Æ ȯÀÚÀÇ Ä¡·á¸¦ Àü¹®À¸·Î ÇÏ´Â ½ÉÀå ¼ö¼úÀ» À§ÇØ ¼³°èµÈ ÃÖ÷´Ü ÀÇ·á±â±âÀÎ POLAR Cryoablation SystemÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº Á¶Á÷À» µ¿°á½ÃÄÑ º´º¯À» ¸¸µé°í ½ÉÀåÀÇ ºñÁ¤»óÀûÀÎ Àü±â °æ·Î¸¦ Â÷´ÜÇÏ´Â Å©¶óÀÌ¿À ÀýÁ¦ ±â¼úÀ» ÀÌ¿ëÇÕ´Ï´Ù. FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Æ Boston ScientificÀº ¼Ò¾Æ ½ÉÀå ¼ö¼úÀÇ Áøº¸¿¡ Áß¿äÇÑ ÀÌÁ¤Ç¥¸¦ ´Þ¼ºÇß½À´Ï´Ù.
¶ÇÇÑ ¼Ò¾Æ ½ÉÀåÇ÷°ü Àå¾ÖÀÇ Áö½ÄÀ» ³ÐÈ÷±â À§ÇÑ °è¸ù Ȱµ¿µµ Ȱ¹ßÇØÁö°í ÀÖÀ¸¸ç, ¼Ò¾Æ ½ÉÀåÇ÷°ü Àå¾Ö¸¦ À§ÇÑ ÀÇ·á ½Ã¼³µµ ¼¼°èÀûÀ¸·Î Á¤ºñµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Áß¿äÇÑ ±¹Á¦ Çà»çÀÎ World Congress of Pediatric Cardiology and Cardiac Surgery°¡ 2023³â 8¿ù¿¡ °³ÃֵǾú½À´Ï´Ù. ÀÌ Çà»ç¿¡´Â ¼¼°è ¼öõ ¸íÀÇ ¼Ò¾Æ ¼øÈ¯±â Àü¹®ÀÇ¿Í ¼Ò¾Æ ½ÉÀå ¼ö¼ú Àǻ簡 ¸ðÀδÙ. ÀÌ È¸ÀÇ´Â ¼Ò¾Æ ¹× ¼±Ãµ¼º ½ÉÀå Áúȯ¿¡ °üÇÑ °¡Àå Á¾ÇÕÀûÀ̰í ÃÖ½ÅÀÌ¸ç ±â¼úÀûÀ¸·Î ÁøÇàµÈ ȸÀÇ·Î °£Áֵ˴ϴÙ. ¼Ò¾Æ ½ÉÀ庴 ȯÀÚÀÇ Äɾî Çâ»óÀ» ÇâÇØ, Àü¹®°¡°¡ Áö½ÄÀ» °øÀ¯ÇØ, Áøº¸¿¡ ´ëÇØ ³íÀÇÇØ Çù·ÂÇÏ´Â Àå¼Ò¸¦ Á¦°øÇÏ´Â ´ë¸ÁÀÇ ÁýȸÀÔ´Ï´Ù.
¶ÇÇÑ 2023³â 7¿ù¿¡ ³×´ú¶õµå¿¡¼ ¼Ò¾Æ½ÉÀå¿Ü°úÀÇ ÀÏ¿øÈ¸¦ ÀÎÁ¤ÇÏ´Â ÆÇ°áÀÌ ÃÖ±Ù ³»·ÁÁ³À¸³ª ÀÌ´Â ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ °áÁ¤Àº ÀÇ·á ÀÎÇÁ¶ó, Àü¹® ÀÇ·á¿¡ ´ëÇÑ È¯ÀÚ Á¢±Ù, ÀÇ·á Á¦°ø¾÷ü °£ÀÇ °æÀï, ¼Ò¾Æ ½ÉÀå ¼ö¼ú ±â¼ú ¹× ±â¼úÀÇ ¹ßÀü µî ½ÃÀåÀÇ ´Ù¾çÇÑ Ãø¸é¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
Pediatric Cardiac Surgery Market Trends
The global pediatric cardiac surgery market size was estimated at USD 15.6 billion in 2023 and is projected to grow at a CAGR of 9.8% from 2024 to 2030. The market's growth is primarily driven by the rising incidence of congenital heart defects and heart failure in children. According to the State of Victoria, approximately 1% of newborns are born with a congenital heart defect (CHD), with more than half of these cases requiring treatment due to the severity of the condition. Moreover, as per the Pan American Health Organization study published in March 2023, in the first four weeks of life, an estimated 303,000 newborns die worldwide due to congenital anomalies.
Moreover, increasing enhancements in CPB circuit design, monitoring techniques, perfusion methods, temperature control, and myocardial protection have improved clinical outcomes in pediatric cardiac surgeries. For instance, in April 2024, LivaNova launched the Essenz Perfusion System, a cutting-edge system designed to support open-heart surgery procedures in adult and pediatric patients. It integrates the advanced Essenz Heart-Lung Machine (HLM) with an intuitive Patient Monitor and precise sensing technology. This integration enables data-driven decision-making for safe cardiopulmonary bypass (CBP) management.
Innovations such as specialized pediatric perfusion systems, neonatal CPB oxygenators, low prime volume oxygenators, and integrated arterial filters have improved outcomes and expanded treatment options for complex congenital heart abnormalities in newborns and young children. For instance, in November 2023, Ortho-Clinical Diagnostics announced a 510(k) premarket notification by the FDA for a medical device called "VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrators." The purpose of these 510(k) submissions is to demonstrate that the VITROS HIV Combo Reagent Pack and Calibrators are substantially equivalent to a predicate device, the VITROS ECi/ECiQ Immunodiagnostic System HIV Combo Assay.
The government is invested in improving pediatric cardiac surgical facilities, further propelling the market growth. For instance, in October 2023, new recommendations were released in the field of congenital heart surgery and were developed under the leadership of the Congenital Heart Surgeons' Society (CHSS). This society is a prestigious organization comprising leading experts in the field. The collaboration involved 15 prominent medical and surgical societies, indicating a comprehensive and multidisciplinary approach to formulating these recommendations.
Increasing investments and funding for producing pediatric perfusion products have also played a crucial role in driving the market growth. Companies are developing cutting-edge procedures and technologies tailored specifically for pediatric CPB, enhancing the quality of care and expanding the range of available treatment options. For instance, in August 2023, Boston Scientific launched the POLAR Cryoablation System, a cutting-edge medical device designed for cardiac surgery, specifically for treating pediatric patients with congenital heart defects. This system utilizes cryoablation technology, which involves freezing tissue to create lesions that can interrupt abnormal electrical pathways in the heart. By receiving FDA approval, Boston Scientific has achieved a significant milestone in advancing pediatric cardiac surgery.
Moreover, there are growing awareness programs for spreading the knowledge and availability of several healthcare facilities for pediatric cardiovascular disorders globally. For instance, the World Congress of Pediatric Cardiology and Cardiac Surgery, a significant international event, was held in August 2023. This event brings together thousands of pediatric cardiologists and pediatric cardiac surgeons from around the world. This congress is considered the most comprehensive, up-to-date, and technologically advanced meeting for pediatric and congenital heart disease. It is a highly anticipated gathering that provides a platform for professionals to engage, share knowledge, discuss advancements, and collaborate on improving care for pediatric patients with heart conditions.
In addition, the recent court ruling in July 2023, allowing the centralization of pediatric heart surgery in the Netherlands, is likely to impact the market significantly. This decision will influence various market aspects, including healthcare infrastructure, patient access to specialized care, competition among healthcare providers, and advancements in pediatric cardiac surgery techniques and technologies.
Global Pediatric Cardiac Surgery Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pediatric cardiac surgery market report based on procedure, end-use, and region:
U.S.
Canada
Mexico
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Japan
China
India
Australia
South Korea
Thailand
Brazil
Argentina
South Africa
Saudi Arabia
UAE
Kuwait